New drug combo shrinks tumors in most patients facing aggressive cancer type

Pairing an experimental pill with standard chemotherapy shrank tumors or halted growth in most patients with advanced pancreatic cancer, according to early clinical trial results presented Friday at a major international cancer conference.The findings, shared at the EORTC-NCI-AACR Symposium in Barcelona, come from a phase 1/2 trial testing a daily oral medication called daraxonrasib, along with two standard intravenous chemotherapy drugs, gemcitabine and nab-paclitaxel.The trial focused on 61 patients whose pancreatic cancer had already spread to other organs and who had not yet received treatment for their advanced disease.PANCREATIC CANCER PATIENT BEN SASSE SEES 'MASSIVE' TUMOR REDUCTION WITH EXPERIMENTAL NEW DRUGPancreatic cancer is notoriously difficult to treat, because more than half of patients are diagnosed after the disease has already spread, research shows.In major clinical trials for metastatic pancreatic cancer, chemotherapy alone shrinks tumors in about 23% to 42% of patients, but the disease typically begins growing again after five to six months, and most patients survive between eight and 11 months.Combining an experimental daily pill called daraxonrasib with standard chemotherapy shrank tumors or stopped cancer growth in 90.2% of patients with untreated, advanced pancreatic cancer.(iStock)According to National Cancer Institute data, only about 3% of patients with distant-stage disease live five years past diagnosis.In the new study, which tracked patients for a median follow-up of 18 months, tumors shrank in 60.7% of cases, including 8.2% where they disappeared entirely on scans.

Overall, the combination stopped tumor growth in 90.2% of participants.FDA APPROVES ONCE-DAILY PILL FOR DEADLY CANCER AFTER PATIENTS' SURVIVAL RATES NEARLY DOUBLEPatients went a median of 12.8 months before their cancer worsened, almost double the timeframe typically seen with standard chemotherapy, and 76.6% were still alive at the one-year mark, the study found."We are ...

Read More 
PaprClips
Disclaimer: This story is auto-aggregated by a computer program and has not been created or edited by PaprClips.
Publisher: Fox News

Recent Articles